Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 146-157

  Critchley, David John ^a   Aluri, Jagadeesh ^b   Boyd, Peter ^a   Whayman, Matthew ^a   Narurkar, Milind ^b   Delargy, Hugh ^a   Bibbiani, Francesco ^b  

^a EISAI CO LTD   (Japan)

^b EISAI INC   (United States)

Author keywords

Bioavailability; Bioequivalence; Oral; Rufinamide; Suspension; Tablet

Indexed keywords

RUFINAMIDE;

ADULT; ARTHRALGIA; ARTICLE; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; MALE; NORMAL HUMAN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SINGLE DRUG DOSE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; EUROPE; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; SUSPENSIONS; TABLETS; THERAPEUTIC EQUIVALENCY; TRIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 79952526414     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.016     Document Type: Article

References (20)

1. Banzel 2010, Eisai Inc, Woodcliff Lake, NJ, [prescribing Information]. Accessed January 2011. http://www.banzel.com/Docs/Pdf/BanzelPI.pdf.
2. Perucca E., Cloyd J., Critchley D., Fuseau E. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008, 49:1123-1141.
3. Arzimanoglou A., French J., Blume W.T., et al. Lennox-Gastaut syndrome: A consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009, 8:82-93.
4. Florence A.T., Attwood D. Section 1.6: Biopharmaceutical importance of particle size. Physiochemical Principles of Pharmacy 2006, Pharmaceutical Press, London, UK. 4th ed.
5. Section 5.1.3: Efficacy of Antimicrobial Preservation. European Pharmacopoeia 2007, Council of Europe, European Directorate for the Quality of Medicines, Strasbourg, France. 6th ed.
6. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products- general considerations US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Revision 1, Accessed August 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
7. Guideline on the investigation of bioequivalence European Medicines Agency (EMEA), Accessed August 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
8. Guidance for industry: Food-effect bioavailability and fed bioequivalence studies US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Accessed October 2010. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf.
9. Inovelon tablets. Summary of product characteristics Eisai ltd, Accessed January 2011. http://www.medicines.org.uk/EMC/medicine/20165/SPC/Inovelon+Tablets/.
10. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use), Accessed January 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf.
11. Recommended safe limits of alcohol Patient UK, Accessed January 2011. http://www.patient.co.uk/health/Recommended-Safe-Limits-of-Alcohol.htm.
12. PD-LAB-Standards v2.01 2009 Clinical Pathology Accreditation, Accessed January 2011. http://www.cpa-uk.co.uk/files/PD-LAB-Standards_v2.01_Mar_09.pdf.
13. Section 2.9.3: Dissolution: Solid oral dosage forms. European Pharmacopoeia 2007, Council of Europe, European Directorate for the Quality of Medicines, Strasbourg, France. 6th ed.
14. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987, 15:657-680.
15. Kalbag J.B., Chang S.-W., Yeh C.-M. A randomized, open-label, three-way crossover trial to compare the relative bioavailability of rufinamide oral suspension and rufinamide tablets in healthy subjects August 22, 2000, Novartis Pharmaceuticals Corporation, East Hanover, NJ, [unpublished report].
16. Gibaldi M., Perrier D. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics 1982, 409-417. Marcel Dekker, New York, NY. 2nd ed. M. Gibaldi, D. Perrier (Eds.).
17. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2007, Swedish Pharmaceutical Press, Stockholm, Sweden. 4th ed.
18. Guidance for industry: Statistical approaches to establishing bioequivalence US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Accessed October 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
19. Senn S. Cross-Over Trials in Clinical Research 2002, Wiley, New York, NY. 2nd ed.
20. International Conference on Harmonisation (ICH). MedDRA® the Medical Dictionary for Regulatory Activities. Version 11.1.